COVID-19 ECHO Session #46: The Global Access Diagnostics COVID-19 Antigen Rapid Diagnostic Test, COVIOS

September 3, 2021

On 2 September 2021, this COVID-19 ECHO session was convened to share details on the COVIOS antigen rapid diagnostic test (Ag RDT) technology, status of regulatory approval, requirements/consumables to operate the test, and how Ag RDTs can be deployed to support testing programmes for COVID-19 epidemic control. COVIOS, developed by the Global Access Diagnostics, a nonprofit social enterprise for SARS-CoV-2 Ag RDTs, provides a lower cost and more flexible way to deploy testing programs in healthcare facilities, communities, and other settings, ensuring access to vulnerable populations and contributing to effective epidemic control. Presenters for this session include Mark Radford, Executive Director, Global Access Diagnostics and Dr Emily Adams, Director of Epidemic and Neglected Diseases, Mologic and Global Access Diagnostics. Please follow the links here to view the recorded ECHO session and download the presentation slides. Please note that ASLM does not endorse specific manufacturers or service providers. This session is for informational purposes only.